In a recent study published in the journal Proceedings of the National Academy of Sciences, a team of researchers from Yale University's School of Medicine and Harvard University used murine models to assess whether intranasally administered neomycin sulfate could evoke antiviral protection against respiratory viruses such as influenza A and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inducing the expression of ISGs or interferon-stimulated genes.
Study: Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Image Credit: TG23 / Shutterstock Neomycin Sulfate
Respiratory viruses are a group of pathogens belonging to numerous viral families and present a serious threat to human health, primarily because they transmit through droplets and aerosolized respiratory secretions. The gravity of the threat from respiratory viruses was highlighted by the coronavirus disease 2019 (COVID-19) pandemic, where SARS-CoV-2 claimed close to seven million lives across the world and infected over 700 million people. Additionally, influenza viruses are responsible for annual global mortality and morbidity counts of 500,000 and five million cases, respectively.
However, despite significant advances in developing vaccines and therapies against respiratory viruses, these pathogens remain a serious public health concern. The availability of medicines to treat respiratory viral infections is also inequitable worldwide. Furthermore, most treatment options such as antivirals, immunomodulatory agents, convalescent plasma therapy, and monoclonal antibodies only mitigate the progression of the disease once the infection has been established and are not used as prophylaxis or treatment to arrest the infection before it progresses into the lower respiratory tract.
In the present study, the researchers investigated whether the intranasal administration of neomycin sulfate or neomycin in mice evoked protection against influenza A virus and SARS-CoV-2 by inducing the expression of ISGs. Neomycin is an aminoglycoside antibiotic that can induce the expression of ISGs. ISGs are effector proteins activated by interferons (IFN) and hinder the viral life cycle, protecting against viral infections.
Respiratory viral infections often become severe because of the inability of the host to induce timely ISG responses in the upper respiratory tract and clear the virus before it moves to the lower respiratory tract. Furthermore, therapeutic strategies to mount an ISG-based immune response against respiratory viruses in the nasal mucosa and the upper respiratory tract have also not been adequately explored.
Here, the researchers explored whether intranasally administered neomycin also blocks the transmission of the virus in mice models and whether topically applying Neosporin, an antibiotic ointment containing neomycin, can induce the expression of ISGs in human nasal mucosa.
Mice were intranasally treated with a 2mg dose of neomycin, and the nasal turbinate tissues were collected from euthanized mice and evaluated for ISG expression using ribonucleic acid (RNA) fluorescence in situ hybridization. Germ-free mice models were also treated with neomycin to determine whether the expression of ISGs mediated by neomycin depended on the host's commensal microbiota. The secretion levels of interferon types I, II, and III — IFN-α, IFN-β, and IFN-γ, respectively — in the nasal mucosa were also measured to determine whether the expression of ISGs mediated by neomycin was dependent on activation by interferons.
The murine model of SARS-CoV-2 infection, which expresses the human angiotensin-converting enzyme-2 (ACE-2 receptor, and the murine model of influenza infection were used to assess the prophylactic efficacy of intranasally administered neomycin.
The results reported that the intranasal administration of neomycin, either as a prophylactic or therapeutic option, protected the mice from upper respiratory tract infections and severe SARS-CoV-2 infection. Intranasal neomycin also protected the mice from both upper and lower respiratory tract infections when infected with a virulent influenza A strain.
Neomycin was also found to prevent the transmission of SARS-CoV-2 through contact. Additionally, the application of Neosporin ointment was found to induce ISG expression in the human nasal mucosa, providing evidence that intranasal administration of neomycin could induce ISG expression in humans, potentially protecting against viral infections in the upper respiratory mucosa.
Furthermore, the experiments with germ-free mice showed that the expression of ISGs mediated by neomycin was found to be independent of any role played by commensal bacteria in the host microbiome. Moreover, none of the interferons were induced significantly after intranasal administration of neomycin, suggesting that the induction of ISG expression by neomycin was also independent of interferons.
Overall, the findings suggested that intranasal administration of neomycin in murine models induced robust expression of ISGs, which protect against respiratory viruses such as influenza and SARS-CoV-2. This expression of ISGs is independent of host microbiota or interferon-related pathways. These results highlight the potential of neomycin to be used as a therapeutic or prophylactic agent against respiratory viruses.
Posted in: Medical Research News | Disease/Infection News | Pharmaceutical News
Tags: Angiotensin, Antibiotic, Antibodies, Bacteria, Convalescent Plasma, Coronavirus, covid-19, Efficacy, Enzyme, Fluorescence, Genes, Hybridization, Immune Response, immunity, Immunomodulatory, Influenza, Interferon, Interferons, Medicine, Microbiome, Mortality, Pandemic, Prophylaxis, Public Health, Receptor, Respiratory, Respiratory Tract Infections, Ribonucleic Acid, RNA, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, Virus
Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.
Please use one of the following formats to cite this article in your essay, paper or report:
Sidharthan, Chinta. (2024, April 24). Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections. News-Medical. Retrieved on May 24, 2024 from https://www.news-medical.net/news/20240424/Repurposed-nasal-antibiotic-neomycin-shows-promise-in-preventing-and-treating-respiratory-viral-infections.aspx.
Sidharthan, Chinta. "Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections". News-Medical. 24 May 2024. <https://www.news-medical.net/news/20240424/Repurposed-nasal-antibiotic-neomycin-shows-promise-in-preventing-and-treating-respiratory-viral-infections.aspx>.
Sidharthan, Chinta. "Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections". News-Medical. https://www.news-medical.net/news/20240424/Repurposed-nasal-antibiotic-neomycin-shows-promise-in-preventing-and-treating-respiratory-viral-infections.aspx. (accessed May 24, 2024).
Sidharthan, Chinta. 2024. Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections. News-Medical, viewed 24 May 2024, https://www.news-medical.net/news/20240424/Repurposed-nasal-antibiotic-neomycin-shows-promise-in-preventing-and-treating-respiratory-viral-infections.aspx.
In this interview conducted at Pittcon 2024 in San Diego, we spoke to this year's Keynote Speaker Professor Omowunmi (Wunmi) Sadik about how sustainable nanomaterials are transforming human health.
In this interview, Dr. Fu Wei, Director of Quality Management Department at BGI Genomics talks to AZoMedical about achieving and maintaining ISO/IEC 27001 and BS 10012 certifications.
In this interview, Dr. Church, the Molecular and Pediatric Pathologist at Boston Children's Hospital, talks to NewsMedical about their work in pediatric oncology, and the need to expand research and clinical options for children with cancer.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2024
Your AI Powered Scientific Assistant
Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.
A few things you need to know before we start. Please read and accept to continue.
Azthena may occasionally provide inaccurate responses. Read the full terms.
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Agmatine Sulfate Read the full Terms & Conditions.